Multi-target collaboration with UCB in neurodegenerative and neurological diseases announced

Evotec AG today announced that it has entered into a three year integrated drug discovery collaboration with UCB to identify small molecule modulators of priority biological targets, selected by UCB, involved in CNS disorders. Die Original-Meldung zu diesem Chemie Unternehmen finden Sie unter https://www.evotec.com/en/investor-relations/news/corporate-news/p/multi-target-collaboration-with-ucb-in-neurodegenerative-and-neurological-diseases-announced-5012

Weiterlesen

Milestone in an Ion Channel Drug Discovery Collaboration with Ono Pharmaceutical Co., Ltd. achieved

Evotec AG today announced the achievement of specific success criteria in an ion channel research collaboration with Ono Pharmaceutical Co., Ltd. and the receipt of a milestone payment.  Die Original-Meldung zu diesem Chemie Unternehmen finden Sie unter https://www.evotec.com/en/investor-relations/news/corporate-news/p/milestone-in-an-ion-channel-drug-discovery-collaboration-with-ono-pharmaceutical-co-ltd-achieved-5010

Weiterlesen

Medicinal Chemistry Collaboration with Active Biotech

Evotec AG today announced that it has entered into a medicinal chemistry collaboration with Active Biotech AB, following the successful conclusion of a High Throughput Screening campaign to identify small molecule modulators of a priority biological target, selected by Active Biotech, involved in immune disorders and cancer. Die Original-Meldung zu diesem Chemie Unternehmen finden Sie unter https://www.evotec.com/en/investor-relations/news/corporate-news/p/medicinal-chemistry-collaboration-with-active-biotech-5006

Weiterlesen

Ad hoc:Evotec acquires compound management business from Galapagos

Hamburg, Germany – Evotec AG (Frankfurt Stock Exchange, TecDAX, ISIN: DE 000 566480 9) and Galapagos NV (Euronext: GLPG) today announced that Evotec has acquired Compound Focus, Inc., the compound management business of BioFocus, … Die Original-Meldung zu diesem Chemie Unternehmen finden Sie unter https://www.evotec.com/en/investor-relations/news/ad-hoc-releases/p/ad-hocevotec-acquires-compound-management-business-from-galapagos-5595

Weiterlesen

Milestone received as Boehringer Ingelheim starts Phase I clinical trial in Pain

Evotec AG today announced that a back-up compound in its strategic alliance with Boehringer Ingelheim has advanced into a Phase I clinical trial. Evotec will receive a milestone payment of EUR 2.0 million. Die Original-Meldung zu diesem Chemie Unternehmen finden Sie unter https://www.evotec.com/en/investor-relations/news/corporate-news/p/milestone-received-as-boehringer-ingelheim-starts-phase-i-clinical-trial-in-pain-5002

Weiterlesen

Strategic Alliance with PsychoGenics entered to Provide Integrated CNS Drug Discovery Solutions

Evotec AG today announced that it has entered into a strategic alliance with PsychoGenics Inc. to provide integrated CNS drug discovery solutions to pharmaceutical and biotech companies. Die Original-Meldung zu diesem Chemie Unternehmen finden Sie unter https://www.evotec.com/en/investor-relations/news/corporate-news/p/strategic-alliance-with-psychogenics-entered-to-provide-integrated-cns-drug-discovery-solutions-5000

Weiterlesen

Phase II study with NR2B sub-type selective NMDA antagonist in treatment-resistant depression voluntarily terminated

Evotec AG and Roche today decided to voluntarily terminate the first proof-of-concept study in treatment-resistant depression with their NR2B sub-type selective NMDA antagonist EVT 101. Die Original-Meldung zu diesem Chemie Unternehmen finden Sie unter https://www.evotec.com/en/investor-relations/news/corporate-news/p/phase-ii-study-with-nr2b-sub-type-selective-nmda-antagonist-in-treatment-resistant-depression-voluntarily-terminated-4998

Weiterlesen

Ad hoc: Phase II study with NR2B sub-type selective NMDA antagonist in treatment-resistant depression voluntarily terminated

Hamburg, Germany – Evotec AG (Frankfurt Stock Exchange, TecDAX, ISIN: DE 000 566480 9) and Roche today decided to voluntarily terminate the first proof-of-concept study in treatment-resistant depression with their NR2B sub-type … Die Original-Meldung zu diesem Chemie Unternehmen finden Sie unter https://www.evotec.com/en/investor-relations/news/ad-hoc-releases/p/ad-hoc-phase-ii-study-with-nr2b-sub-type-selective-nmda-antagonist-in-treatment-resistant-depression-voluntarily-terminated-5593

Weiterlesen